Results 21 to 30 of about 32,807 (303)

THE EFFECT OF BROMOCRIPTINE ON C-REACTIVE PROTEIN IN WOMEN WITH HYPERPROLACTINEMIC AMENORRHEA [PDF]

open access: yesThe Medical Journal of Basrah University, 2008
C-reactive protein has become the subject of avid interest in recent years. Increased concentrations of C-reactive protein (CRP) became widely accepted as a risk factor of many inflammatory diseases including atherosclerosis, ischemic vascular diseases ...
Isam Hamo Mahmood
doaj   +1 more source

An approach for identifying brainstem dopaminergic pathways using resting state functional MRI. [PDF]

open access: yes, 2014
Here, we present an approach for identifying brainstem dopaminergic pathways using resting state functional MRI. In a group of healthy individuals, we searched for significant functional connectivity between dopamine-rich midbrain areas (substantia nigra;
D'Esposito, Mark   +3 more
core   +3 more sources

Bromocriptine in Parkinsonism. [PDF]

open access: yesBMJ, 1978
A review of the effects of using bromocriptine in Parkinson's disease showed that it rarely helps patients not primarily improved by levodopa. Patients who show late failure with levadopa and whose response to treatment is declining are helped by combining the two drugs.
John Pearce, Iris Pearce
openaire   +3 more sources

Caveolin-1 sensitizes rat pituitary adenoma GH3 cells to bromocriptine induced apoptosis

open access: yesCancer Cell International, 2007
Background Prolactinoma is the most frequent pituitary tumor in humans. The dopamine D2 receptor agonist bromocriptine has been widely used clinically to treat human breast tumor and prolactinoma through inhibition of hyperprolactinemia and induction of ...
Huang Mu-Chiou   +7 more
doaj   +1 more source

Effect of bromocriptine on glycemic control, risk of cardiovascular diseases and weight in patients with type 2 diabetes: a systematic review

open access: yesDiabetology & Metabolic Syndrome, 2023
Background Type 2 diabetes (T2DM) patients, including those in good glycemic control, have an increased risk of cardiovascular disease (CVD). Maintaining good glycemic control with drugs may reduce long-term CVD risk.
Mulualem Tesfaye Birhan   +3 more
doaj   +1 more source

Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study

open access: yesEuropean Heart Journal, 2017
Aims An anti-angiogenic cleaved prolactin fragment is considered causal for peripartum cardiomyopathy (PPCM). Experimental and first clinical observations suggested beneficial effects of the prolactin release inhibitor bromocriptine in PPCM.
D. Hilfiker-Kleiner   +20 more
semanticscholar   +1 more source

Bromocriptine Use in Peripartum Cardiomyopathy: Review of Cases

open access: yesAmerican Journal of Perinatology Reports, 2018
Objective This study is to review published cases of peripartum cardiomyopathy (PPCM) treated with bromocriptine and outline pros and cons of the treatment strategy.
Rebecca Simon   +2 more
doaj   +1 more source

Rapid and dramatic glucose‐lowering effect of bromocriptine in an inadequately controlled type 2 diabetes patient with prolactinoma

open access: yesJournal of Diabetes Investigation, 2021
Dopamine receptor agonists are typically used to treat Parkinson’s disease and certain pituitary tumors, such as prolactinoma or a growth hormone‐producing tumor.
Motoyuki Igata   +8 more
doaj   +1 more source

Peripartum cardiomyopathy: diagnosis and management [PDF]

open access: yes, 2017
No abstract ...
Coats, Caroline J.   +5 more
core   +1 more source

Effects of Bromocriptine on Glucose and Insulin Dynamics in Normal and Insulin Dysregulated Horses

open access: yesFrontiers in Veterinary Science, 2022
The objectives of the study were to study the effects of the synthetic ergot alkaloid (EA), bromocriptine, on glucose and lipid metabolism in insulin dysregulated (ID, n = 7) and non-ID (n = 8) mares. Horses were individually housed and fed timothy grass
Caroline M. M. Loos   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy